- Home
- SVRN vs MBRX Comparison
SVRN vs MBRX Comparison
Compare SVRN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | MBRX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Greece | United States |
| Employees | 87 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 13.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SVRN | MBRX |
|---|---|---|
| Price | $10.57 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 29.2K | ★ 227.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.25 |
| 52 Week High | $15.07 | $7.98 |
Technical Indicators
Market Signals| Indicator | SVRN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 59.86 |
| Support Level | $8.16 | $2.27 |
| Resistance Level | $12.73 | $2.95 |
| Average True Range (ATR) | 1.39 | 0.22 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 62.97 | 63.11 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.